Amgen announced positive results from clinical trials of two separate drugs in late August. On Aug. 30, the Thousand Oaks-based biotech giant said its Phase 3 trail evaluating daily oral doses of Lumakras, a treatment for non-small cell lung cancer, 'met its primary endpoint of progression-free survival' and demonstrated statistically significant superiority over the current standard chemotherapy treatment. The study assessed the effects of Lumakras on 345 patients with non-small cell lung cancer who had previously been traded with chemotherapy.

https://www.pacbiztimes.com/2022/09/01/amgen-reports-pair-of-positive-clinical-trial-results/

#pacbiztimes